23:21 , Nov 30, 2017 |  BC Week In Review  |  Company News

Amgen buys out Kyowa JV

In October, Amgen Inc. (NASDAQ:AMGN) and Kirin Holdings Co. Ltd. terminated their JV Kirin-Amgen, which now becomes a wholly-owned subsidiary of Amgen. Kirin is the parent company of Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). Kirin...
23:25 , Sep 13, 2017 |  BC Extra  |  Preclinical News

Autism-like behavior linked to Th17 cells in maternal gut microbiome

Scientists showed that intestinal bacteria-induced activation of T helper type 17 (Th17) cells in the gut of pregnant mice affects development of the primary somatosensory cortex and leads to autism-like behaviors in offspring. The two...
12:26 , May 26, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends approval of Leo's Kyntheum for plaque psoriasis

EMA’s CHMP recommended approval of an MAA from Leo Pharma A/S (Ballerup, Denmark) for Kyntheum brodalumab (Lumicef - Japan) (KHK4827) to treat moderate to severe plaque psoriasis in adults who are eligible for systemic therapy....
23:20 , May 19, 2017 |  BC Extra  |  Company News

CHMP backs approval of Veltassa, other candidates

On Friday, EMA's CHMP recommended approval of several therapies, including hyperkalemia drug Veltassa patiromer, psoriasis drug Kyntheum brodalumab and schizophrenia treatment Reagila cariprazine . The committee also issued a negative opinion for colorectal cancer candidate...
18:45 , May 10, 2017 |  BC Week In Review  |  Clinical News

Kyowa starts Phase III of brodalumab in axial spondyloarthritis

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) began a Phase III trial evaluating subcutaneous Lumicef brodalumab (KHK4827) to treat axial spondyloarthritis. The double-blind, placebo-controlled, Asian trial is evaluating the primary endpoint of the proportion of patients...
21:07 , Apr 27, 2017 |  BC Week In Review  |  Company News

Valeant sales and marketing update

Valeant priced psoriasis treatment Siliq brodalumab at a wholesale acquisition cost (WAC) of $3,500 per month, which it said is the lowest for a marketed injectable biologic psoriasis treatment. Competitor Humira adalimumab from AbbVie Inc....
22:05 , Apr 21, 2017 |  BC Extra  |  Company News

Valeant prices Siliq

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) priced psoriasis treatment Siliq brodalumab at a wholesale acquisition cost (WAC) of $3,500 per month, which it said is the lowest for a marketed injectable biologic psoriasis treatment. Competitor...
15:01 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; inflammation

INDICATION: Psoriasis; multiple sclerosis (MS); asthma In vitro and mouse studies identified an inhibitor of the IL-17 / IL-17R interaction that could help treat psoriasis, MS and asthma. In silico screening for compounds that interact...
19:53 , Feb 17, 2017 |  BC Week In Review  |  Clinical News

Siliq regulatory update

FDA approved a BLA from Valeant for Siliq brodalumab to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond or have stopped responding...
17:36 , Feb 16, 2017 |  BC Extra  |  Company News

FDA approves Valeant's psoriasis drug with warning, REMS

FDA approved Siliq brodalumab from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to treat adults with moderate to severe plaque psoriasis. Next half, the company expects to launch the IgG2 mAb against IL-17 receptor (IL17R; IL17RA...